Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Biogen Idec Signs Up UCB as China Marketing Partner

publication date: Jan 31, 2014
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Biogen Idec out-licensed China and Southeast Asia rights for an eight-drug portfolio to UCB, the Belgian global pharma. The portfolio consists of six treatments for multiple sclerosis and two recombinant treatments for hemophilia. UCB will conduct clinical trials of the products in China to obtain CFDA approval. Because UCB concentrates on immune and central nervous system disorders, the company is a natural fit for Biogen Idec’s portfolio of MS drugs. More details....

Stock Symbols: (NSDQ: BIIB) (Euronext: UCB)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...